翔宇医疗 - Financials

翔宇医疗 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017
+Revenue	744.0M	745.0M	489.0M	523.0M	496.0M	427.0M	359.0M	289.0M
Revenue Growth %	-0.1%	52.4%	-6.5%	5.4%	16.2%	18.9%	24.2%	--
Total Revenue	744.0M	745.0M	489.0M	523.0M	496.0M	427.0M	359.0M	289.0M
Cost Of Revenue	242.0M	234.0M	165.0M	166.0M	160.0M	144.0M	131.0M	117.0M
+Gross Profit	502.0M	511.0M	324.0M	357.0M	336.0M	283.0M	228.0M	172.0M
Gross Margin %	67.5%	68.6%	66.3%	68.3%	67.7%	66.3%	63.5%	59.5%
Total Operating Cost	670.0M	545.0M	420.0M	364.0M	325.0M	317.0M	293.0M	223.0M
Selling Expenses	215.0M	170.0M	141.0M	109.0M	88.3M	94.3M	97.1M	61.3M
Admin Expenses	60.2M	41.0M	35.9M	32.0M	26.6M	31.3M	28.6M	20.5M
Rd Expenses	152.0M	107.0M	92.4M	68.6M	51.6M	41.5M	28.8M	17.4M
Finance Expenses	-23.7M	-29.8M	-26.6M	-24.0M	-12.6M	-4.9M	254,200	343,200
+Operating Income	109.0M	245.0M	135.0M	224.0M	223.0M	147.0M	93.9M	77.5M
Operating Margin %	14.7%	32.9%	27.6%	42.8%	45.0%	34.4%	26.2%	26.8%
Non Operating Income	72,500	1.6M	152,900	96,500	350,300	556,500	445,200	189,100
Non Operating Expenses	1.4M	2.2M	2.6M	1.4M	914,200	291,800	490,200	861,800
Investment Income	1.4M	9.3M	13.7M	12.1M	-310,700	2.1M	2.8M	11,100
Asset Disposal Income	66,500	12,400	--	20,100	11,000	--	--	18,900
Asset Impairment Loss	9.2M	12.1M	6.0M	2.8M	2.2M	3.1M	1.5M	1.0M
Other Income	33.4M	35.2M	53.5M	52.3M	53.0M	34.4M	25.2M	11.0M
Income Before Tax	107.0M	244.0M	133.0M	223.0M	223.0M	147.0M	93.9M	76.9M
Income Tax	4.4M	15.7M	9.7M	23.2M	26.8M	18.5M	13.6M	12.4M
+Net Income	103.0M	228.0M	123.0M	200.0M	196.0M	129.0M	80.3M	64.5M
Net Margin %	13.8%	30.6%	25.2%	38.2%	39.5%	30.2%	22.4%	22.3%
Net Income Attributable	103.0M	227.0M	125.0M	202.0M	196.0M	129.0M	80.3M	64.5M
Minority Interest	-90,500	1.2M	-2.2M	-2.4M	-252,800	-81,900	--	--
Eps Basic	0.66	1.44	0.79	1.35	1.64	1.07	0.67	--
Eps Diluted	0.69	1.46	0.79	1.35	1.64	1.07	0.67	--

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017
Cash And Equivalents	743.0M	664.0M	726.0M	830.0M	487.0M	364.0M	19.7M	18.8M
Trading Financial Assets	--	162.0M	636.0M	648.0M	--	--	--	--
Accounts Receivable	64.8M	53.9M	31.5M	41.2M	28.7M	16.1M	16.5M	5.8M
Notes Receivable	--	976,000	800,000	772,800	--	--	1.6M	600,000
Notes And Accounts Receivable	64.8M	54.9M	32.3M	42.0M	28.7M	16.1M	18.1M	6.4M
Prepayments	28.8M	32.3M	22.2M	25.1M	14.0M	20.2M	23.9M	18.1M
Inventory	238.0M	241.0M	223.0M	159.0M	130.0M	143.0M	133.0M	109.0M
Total Current Assets	1.1B	1.2B	1.7B	1.7B	671.0M	549.0M	411.0M	261.0M
Long Term Equity Investment	13.4M	13.1M	17.1M	16.7M	2.6M	3.1M	--	--
Fixed Assets	--	397.0M	93.9M	93.8M	96.8M	98.1M	97.0M	94.4M
Fixed Assets Total	952.0M	397.0M	93.9M	93.8M	96.8M	98.1M	97.0M	94.4M
Construction In Progress	--	429.0M	314.0M	77.1M	8.4M	--	147,200	5.0M
Construction In Progress Total	252.0M	429.0M	314.0M	77.1M	8.4M	--	147,200	5.0M
Intangible Assets	217.0M	208.0M	204.0M	209.0M	51.6M	44.6M	34.3M	35.3M
Long Term Deferred Expenses	16.6M	5.7M	1.5M	1.5M	481,800	712,900	959,300	998,300
Total Non Current Assets	1.8B	1.4B	700.0M	466.0M	310.0M	175.0M	150.0M	141.0M
Total Assets	2.9B	2.6B	2.4B	2.2B	982.0M	724.0M	561.0M	402.0M
Short Term Borrowings	354.0M	27.0M	17.2M	--	50.0M	--	--	10.0M
Accounts Payable	134.0M	103.0M	96.7M	33.1M	15.9M	22.7M	18.2M	10.2M
Advance Receipts	--	--	--	--	--	48.8M	54.2M	23.2M
Contract Liabilities	128.0M	108.0M	136.0M	64.2M	50.1M	--	--	--
Total Current Liabilities	735.0M	372.0M	352.0M	181.0M	200.0M	145.0M	124.0M	279.0M
Total Non Current Liabilities	138.0M	113.0M	76.4M	55.6M	38.2M	31.7M	22.3M	23.8M
Total Liabilities	873.0M	485.0M	428.0M	237.0M	238.0M	177.0M	147.0M	303.0M
Paid In Capital	160.0M	160.0M	160.0M	160.0M	120.0M	120.0M	120.0M	71.6M
Capital Reserve	1.3B	1.3B	1.3B	1.3B	285.0M	285.0M	282.0M	9.6M
Surplus Reserve	80.0M	80.0M	58.9M	49.1M	28.9M	13.2M	1.4M	13.5M
Retained Earnings	676.0M	656.0M	487.0M	432.0M	309.0M	129.0M	11.4M	4.4M
Minority Equity	16.1M	16.5M	12.3M	10.5M	-231,600	21,100	--	--
Equity Attributable	2.0B	2.1B	1.9B	1.9B	744.0M	547.0M	415.0M	99.1M
Total Equity	2.1B	2.1B	1.9B	1.9B	743.0M	547.0M	415.0M	99.1M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017
Cash From Sales	868.0M	786.0M	653.0M	573.0M	562.0M	484.0M	438.0M	343.0M
Tax Refunds Received	15.8M	17.1M	10.6M	6.6M	5.3M	1.2M	3.1M	103,500
Total Operating Cash Inflow	925.0M	901.0M	746.0M	665.0M	632.0M	544.0M	462.0M	355.0M
Cash Paid For Goods	245.0M	257.0M	200.0M	180.0M	159.0M	153.0M	170.0M	153.0M
Cash Paid To Employees	268.0M	212.0M	192.0M	154.0M	110.0M	99.7M	90.0M	55.1M
Taxes Paid	60.0M	75.5M	54.4M	68.8M	70.6M	58.8M	58.4M	38.5M
Total Operating Cash Outflow	747.0M	673.0M	560.0M	500.0M	416.0M	388.0M	388.0M	295.0M
Operating Cash Flow	179.0M	228.0M	187.0M	166.0M	216.0M	156.0M	74.2M	59.3M
Total Investing Cash Inflow	333.0M	1.8B	2.6B	1.0B	304,100	213.0M	106.0M	42,800
Total Investing Cash Outflow	609.0M	2.0B	2.7B	1.8B	140.0M	24.4M	243.0M	118.0M
Investing Cash Flow	-276.0M	-235.0M	-179.0M	-782.0M	-139.0M	189.0M	-137.0M	-118.0M
Cash From Borrowings	338.0M	75.0M	46.0M	--	50.0M	--	--	10.0M
Dividends And Interest Paid	85.9M	40.5M	60.1M	59.4M	805,800	--	34,400	101.0M
Debt Repayments	189.0M	72.2M	43.0M	50.0M	--	--	10.0M	--
Total Financing Cash Inflow	516.0M	82.0M	64.1M	1.1B	52.3M	103,000	77.4M	180.0M
Total Financing Cash Outflow	368.0M	141.0M	181.0M	131.0M	4.1M	2.8M	14.0M	124.0M
Financing Cash Flow	148.0M	-58.5M	-117.0M	955.0M	48.2M	-2.7M	63.3M	56.4M
Net Change In Cash	51.1M	-65.2M	-109.0M	339.0M	125.0M	342.0M	818,300	-2.1M
Ending Cash Balance	703.0M	652.0M	717.0M	826.0M	487.0M	362.0M	19.7M	18.8M
Capex	439.0M	479.0M	203.0M	134.0M	140.0M	21.1M	7.0M	14.8M